Melanotan I is the older research name for afamelanotide, a synthetic version of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike most compounds in this guide, afamelanotide is FDA-approved: the FDA approved it on October 8, 2019, as Scenesse, a prescription implant for adults with a rare light-sensitivity disorder. It is not approved for cosmetic tanning.
Alpha-MSH is a natural hormone that tells pigment cells in the skin to make melanin. It does this by binding to the melanocortin-1 receptor (MC1R). Afamelanotide differs from the natural hormone at two positions in its amino acid chain, which makes it more potent and longer-lasting. It raises levels of eumelanin, the brown-black form of melanin, without the need for sun exposure.
Afamelanotide was created in the early 1980s by researchers at the University of Arizona. The rights were licensed to an Australian company, Epitan, which changed its name to Clinuvel in 2006. It was authorized in the European Union in 2014 for erythropoietic protoporphyria (EPP), five years before the U.S. approval.
EPP is a rare inherited condition in which a substance called protoporphyrin IX builds up in the body. When light reaches the skin, it can cause intense pain, redness and swelling. Scenesse is approved to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP. It is placed under the skin by a healthcare professional trained in the procedure.
In the first of the trials the FDA reviewed, 93 people took part. Over 180 days, those receiving Scenesse spent a median of 64 hours in direct sunlight on days with no pain, compared with 41 hours for those on placebo.
Current status: FDA-approved prescription drug (Rx only).
The approval covers Scenesse itself, and its label, last revised in August 2024, is still limited to adults with EPP. Clinuvel is also studying Scenesse in vitiligo; in a July 28, 2026 update, it said topline results from its CUV105 study are expected in December 2026. Vitiligo is not an approved use.
Unapproved products sold online as "melanotan" or "melanotan I" are not Scenesse. The FDA has not reviewed their contents, and the approval does not extend to them. Melanotan I should also not be confused with melanotan II, a different and unapproved compound.
The Scenesse label warns that serious allergic reactions, including anaphylaxis, have been reported. It also warns that afamelanotide may darken existing moles and freckles and recommends a full body skin examination twice a year. Patients are told to keep using sun and light protection.
The most common side effects in trials included reactions at the implant site, nausea, sore throat, cough and fatigue. Because the approval covers adults only, use in children has not been approved, and the FDA has not evaluated afamelanotide for cosmetic tanning.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply afamelanotide, and we do not point readers to anyone who does.
For personal medical questions, including questions about EPP or light sensitivity, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Related melanocortin compounds include melanotan II and PT-141 (bremelanotide), and KPV is a small fragment of alpha-MSH. For more on approvals, read whether peptides are legal in the U.S.